BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pb-DOTAM-GRPR1 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pb-DOTAM-GRPR1\, from ClinicalTrials.gov 
 estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05283330-2829@assetmemo.bio
DTSTAMP:20261121T005442Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pb-DOTAM-GRPR1: Phase 1 readout est. (NCT05283330)
DESCRIPTION:Pb-DOTAM-GRPR1\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: 
 Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Rec
 urrent or Metastatic GRPR-expressing Tumors\nEstimated primary completion:
  January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pb-dot
 am-grpr1#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05283330
URL:https://assetmemo.bio/drug/pb-dotam-grpr1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
